Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma

Duan, Feng; Bai, Yanhua; Cui, Li; Li, Xiaohui; Yan, Jieyu; Wang, Maoqiang

doi:10.4251/wjgo.v12.i1.92

Cited by 11 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 Tandem transplantation, re-resection, radiofrequency ablation, and interventional therapy such as transcatheter hepatic arterial chemoembolization are possible alternative approaches. [8][9][10] After the ASCO in 2019, Lenvatinib is considered to be the first-line recommended treatment for HCC compared with sorafenib. 11 Although the results still unsatisfactory, further observation is needed to determine its long-term effectiveness.…”

Section: Introductionmentioning

confidence: 99%

PD-L1⁺NEUT, Foxp3⁺Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

Zhou

Wang

Lyu

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: This presented study was aimed to evaluate the diagnostic and prognostic value of PD-L1+Neutrophils (PD-L1+NEUT) and neutrophil to lymphocyte ratio (NLR) based on our previous experience of Foxp3+Treg in transplantation. Methods: the NLR cutoff value of 1.79 was used to include 136 cases from the 204 patients with hepatocellular carcinoma (HCC) confirmed by clinical pathology, which were divided into highly-moderately and poorly differentiated HCC groups. The expressions of PD-L1+NEUT and Foxp3+Treg in peripheral blood and cancer tissue were detected with flow cytometry, meanwhile, PD-L1 and Foxp3 expressed in carcinoma and para-carcinoma tissues were marked by immunohistochemistry. Survival rates, including overall survival and disease-free survival, were calculated by the Kaplan–Meier curve and evaluated with the log-rank test. Finally, Cox risk regression model was used to analyze the independent risk factors for prognostic survival. Results: The level of PD-L1+NEUT, Foxp3+Treg, and NLR in peripheral blood of patients with poorly differentiated HCC were significantly increased (all P < .001). Both PD-L1+NEUT and NLR were positively correlated with Foxp3+Treg ( r = 0.479, P = .0017; r = 0.58, P < .0001). The level of PD-L1+NEUT and Foxp3+Treg as well as PD-L1 and Foxp3 in cancer tissue and patients with poorly differentiated HCC were obviously increased (all P < .01), respectively. Cox regression analysis indicated that PD-L1+NEUT, NLR, and Foxp3+Treg were independent risk factors for the prognosis ( P = .000, .000, .006) with a RR and 95%CI of 2.704-(2.155-3.393), 3.139-(2.361-4.173), 1.409-(1.105-1.798), respectively. Conclusion: PD-L1+NEUT, NLR, and Foxp3+Treg are independent risk factors for prognosis which maybe new marker of lower survival benefits.

show abstract

Section: Introductionmentioning

confidence: 99%

PD-L1⁺NEUT, Foxp3⁺Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

Zhou

Wang

Lyu

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…In the present study, the median OS and PFS of TACE for single pHCC (diameter > 5 cm) were 16.8 and 5.8 months, respectively. Duan et al reported that simultaneous TACE and radiofrequency ablation could be a safe yet effective treatment for large HCC (diameter > 8 cm) [23]. Irie et al reported a new TACE technique for large HCC nodules (> 7 cm), which included sparse gelatin slurry under balloon occlusion and repeated alternate infusion of cisplatin solution (RAIB-TACE) [24].…”

Section: Discussionmentioning

confidence: 99%

Pesudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transcatheter Arteial Chemoembolization

Wang

Zuo

et al. 2022

Preprint

View full text Add to dashboard Cite

Background The effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) or trans-arterial chemoembolization (TACE) for cases with single pseudo-capsuled hepatocellular carcinoma (pHCC), as well as their survival outcomes were investigated. Methods 196 cases with single pHCC (diameter > 5 cm) receiving initial HAIC (n = 92) and TACE (n = 104) were enrolled. The propensity score match (PSM) approach based on Cox models was employed to tune any possible imbalance in treatment assignment. The overall survival (OS), objective response rate (ORR), progression-free survival (PFS), and partial response rate (PRR) of the subjects were investigated by using the Log-rank test. The independent risk factors for outcomes were investigated by univariate and multivariate analyses and the results were analyzed by using the Cox regression model. Results The median follow-up of the subjects was 22.3 months. After PSM, no significant difference was found in OS of the HAIC and TACE groups (OS, 16.8 vs. 12.0 months; P = 0.267), while the median PFS of the TACE group was enhanced compared with the HAIC group (PFS, 5.7 vs. 2.8 months; P = 0.003). Moreover, PRR and ORR of the TACE group were enhanced compared with the HAIC group (PRR, 34.6% vs. 21.7%; P = 0.046; ORR, 35.6% vs. 21.7%; P = 0.033). The nomogram model showed high predictive accuracy and significant discrimination. Conclusions TACE therapy could improve the control of tumor progression compared with HAIC for cases with single pHCC.

show abstract

“…In addition, Yttrium-90 radioembolization and Iodine-125 ( 125 I) seed brachytherapy have been adopted to control target lesions[ 29 - 31 ]. TACE combined with systemic therapy or loco-regional therapy revealed favorable outcomes and good tolerance[ 15 , 31 , 32 ].…”

Section: Comprehensive Analyses Of the Endpoints For Tace In Tace Fai...mentioning

confidence: 99%

“…It has been reported that approximately 51.3% of HCC nodules (with an average size of 5 cm) had microvascular invasion (MVI) and 42.4% of the nuclei were severely atypical[ 38 ]. For patients with intermediate- or advanced-stage HCC, early tumor progression after locoregional therapy was almost inevitable due to heavy tumor burden and frequent MVI[ 15 , 32 , 39 ]. Combination therapy was expected to delay tumor recurrence[ 16 ].…”

Section: Comprehensive Analyses Of the Endpoints For Tace In Tace Fai...mentioning

confidence: 99%

Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition

Zhang¹,

Zhong²,

Zhang³

et al. 2022

WJGS

View full text Add to dashboard Cite

Multi-session transarterial chemoembolization (TACE) is usually needed for the treatment of intermediate-stage hepatocellular carcinoma (HCC), but it may not always have a positive influence on prognosis due to high heterogeneity of HCC. To avoid ineffective repeated TACE, the concept of TACE failure/refractoriness has been proposed by several organizations and is being addressed using tyrosine kinase inhibitors. The concept of TACE failure/refractoriness is controversial due to ambiguous definitions and low evidence-based data. To date, only a few studies have examined the rationality concerning the definition of TACE failure/refractoriness, although the concept has been introduced and applied in many TACE-related clinical trials. This review focuses on some of the issues related to different versions of TACE failure/refractoriness, the rationality of related definitions, and the feasibility of continuing TACE after so-called failure/refractoriness based on published evidence. A suggestion to re-define TAEC failure/refractoriness is also put forward.

show abstract

Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma

Cited by 11 publications

References 18 publications

PD-L1⁺NEUT, Foxp3⁺Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

PD-L1⁺NEUT, Foxp3⁺Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

Pesudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transcatheter Arteial Chemoembolization

Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition

Contact Info

Product

Resources

About

Simultaneous transarterial chemoembolization and radiofrequency ablation for large hepatocellular carcinoma

Cited by 11 publications

References 18 publications

PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

Pesudo-capsulated Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transcatheter Arteial Chemoembolization

Transarterial chemoembolization failure/refractoriness: A scientific concept or pseudo-proposition

Contact Info

Product

Resources

About

PD-L1⁺NEUT, Foxp3⁺Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma

PD-L1⁺NEUT, Foxp3⁺Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma